Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caudal S-ketamine for Hypospadias Analgesia
NCT05922605Phase 4Unknown
- Start
- Jun 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in postoperative pain (2 arms). Primary endpoint: Duration of caudal analgesia at 48 hours. Status: unknown.
02
Drugs
esketamine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05922605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05922605.